Seres director granted 7,508 stock options

Seres Therapeutics director Stephen Berenson received a new stock option grant covering 7,508 shares of common stock.

Rhea-AI Filing Summary

Seres Therapeutics director Stephen Berenson received a new stock option grant covering 7,508 shares of common stock. The option has an exercise price of $7.94 per share and was awarded as a compensation-related grant, not an open-market purchase or sale.

The option vests in four equal quarterly installments on October 1, 2026, January 1, 2027, April 1, 2027, and July 1, 2027, with the final vesting date moving to the day before the 2027 annual stockholder meeting if that meeting occurs before July 1, 2027. Vesting is conditioned on Berenson continuing to serve as a non-employee director through each vesting date.

Insider Trade Summary

Grant/Award: 7,508 shares

Grant/Award 1 txn

Insider Berenson Stephen

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	7,508	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 7,508 contracts (Direct)

Footnotes (1)

1. F1. The option vests and becomes exercisable in four equal quarterly installments occurring on October 1, 2026, January 1, 2027, April 1, 2027, and July 1, 2027, provided that if the issuer's 2027 annual meeting of stockholders occurs before July 1, 2027, the final quarterly vesting installment will vest on the day immediately prior to the date of such annual meeting, in each case, subject to the reporting person continuing in service on the Board as a non-employee director through the applicable vesting date.

Key Figures

Option shares granted: 7,508 shares Exercise price: $7.94 per share Shares following transaction: 7,508 option shares +3 more

6 metrics

Option shares granted 7,508 shares Stock option grant to director Stephen Berenson

Exercise price $7.94 per share Stock option exercise price

Shares following transaction 7,508 option shares Total for this award after grant

Option expiration date July 1, 2036 Option expiration

First vesting date October 1, 2026 Initial quarterly vesting installment

Final scheduled vesting date July 1, 2027 Last quarterly vesting, subject to 2027 meeting timing

Key Terms

Stock Option (right to buy), exercise price, non-employee director, vests and becomes exercisable, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 7.9400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

non-employee director financial

"subject to the reporting person continuing in service on the Board as a non-employee director"

vests and becomes exercisable financial

"The option vests and becomes exercisable in four equal quarterly installments"

annual meeting of stockholders financial

"if the issuer's 2027 annual meeting of stockholders occurs before July 1, 2027"

FAQ

What did Seres Therapeutics (MCRB) director Stephen Berenson report in this Form 4?

Stephen Berenson reported receiving a stock option grant for 7,508 shares of Seres Therapeutics common stock. The award is a compensation-related option, not an open-market transaction, and represents his holdings in this specific option after the grant.

What are the key terms of Stephen Berenson’s new Seres Therapeutics stock option?

The stock option covers 7,508 shares of common stock at an exercise price of $7.94 per share. It is a right to buy shares in the future, rather than an immediate share purchase on the open market.

How does the vesting schedule work for the MCRB option granted to Stephen Berenson?

The option vests in four equal quarterly installments on October 1, 2026, January 1, 2027, April 1, 2027, and July 1, 2027. Vesting requires Berenson to continue serving as a non-employee director through each applicable vesting date.

Can the vesting dates of Stephen Berenson’s Seres Therapeutics option change?

Yes, the final quarterly vesting installment may vest earlier. If Seres Therapeutics’ 2027 annual meeting of stockholders occurs before July 1, 2027, that last portion will vest on the day immediately before the date of the 2027 annual meeting.

Is Stephen Berenson buying or selling Seres Therapeutics (MCRB) shares in this Form 4?

He is not buying or selling shares on the market. The filing reports an option grant, categorized as an acquisition of a derivative security as compensation, with no open-market purchase or sale of common stock disclosed.

How many Seres Therapeutics option shares does Stephen Berenson hold after this grant?

After this transaction, Berenson holds 7,508 option shares under this specific award. This total reflects the reported derivative position from the grant, subject to its vesting schedule and future exercisability.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 06:12 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Berenson Stephen

(Last) (First) (Middle)

C/O SERES THERAPEUTICS, INC.

101 CAMBRIDGE PARK DRIVE

(Street)

CAMBRIDGE MASSACHUSETTS 02140

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Seres Therapeutics, Inc. [ MCRB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$7.94	07/01/2026		A		7,508		(1)	07/01/2036	Common Stock	7,508	$0	7,508	D

Explanation of Responses:

1. The option vests and becomes exercisable in four equal quarterly installments occurring on October 1, 2026, January 1, 2027, April 1, 2027, and July 1, 2027, provided that if the issuer's 2027 annual meeting of stockholders occurs before July 1, 2027, the final quarterly vesting installment will vest on the day immediately prior to the date of such annual meeting, in each case, subject to the reporting person continuing in service on the Board as a non-employee director through the applicable vesting date.

	/s/ Thomas J. DesRosier, Attorney-in-Fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)